{"filing":{"accession_number":"0001193125-26-396716","cik":"0001936258","ticker":"NAMSW","company_name":"NewAmsterdam Pharma Co N.V.","form":"8-K","filing_date":"2026-09-21","report_date":"2026-09-21","primary_document":"nams-20260921.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526396716/nams-20260921.htm"},"events":[{"id":34025,"run_id":31322,"accession_number":"0001193125-26-396716","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"The disclosure announces the European Commission's grant of marketing authorization for two obicetrapib formulations (Ubeslo® and Evlarco®), representing the first worldwide regulatory approval of this drug candidate. This is a material operational and commercial milestone for a pharmaceutical company, triggering milestone payments in the \"mid-teens of millions of euros\" and establishing the foundation for commercialization in Europe through the Menarini partnership. While not a traditional M\u0026A transaction or earnings release, this regulatory approval is a transformative operational event that would materially affect investor assessment of the company's pipeline and revenue prospects.","company_name":"NewAmsterdam Pharma Co N.V.","ticker":"NAMSW","filing_date":"2026-09-21","form":"8-K","submitted_at":null,"items":[{"id":37642,"accession_number":"0001193125-26-396716","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The disclosure announces the European Commission's grant of marketing authorization for two obicetrapib formulations (Ubeslo® and Evlarco®), representing the first worldwide regulatory approval of this drug candidate. This is a material operational and commercial milestone for a pharmaceutical company, triggering milestone payments in the \"mid-teens of millions of euros\" and establishing the foundation for commercialization in Europe through the Menarini partnership. While not a traditional M\u0026A transaction or earnings release, this regulatory approval is a transformative operational event that would materially affect investor assessment of the company's pipeline and revenue prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-21T20:31:58.890613+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":37642,"accession_number":"0001193125-26-396716","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"The disclosure announces the European Commission's grant of marketing authorization for two obicetrapib formulations (Ubeslo® and Evlarco®), representing the first worldwide regulatory approval of this drug candidate. This is a material operational and commercial milestone for a pharmaceutical company, triggering milestone payments in the \"mid-teens of millions of euros\" and establishing the foundation for commercialization in Europe through the Menarini partnership. While not a traditional M\u0026A transaction or earnings release, this regulatory approval is a transformative operational event that would materially affect investor assessment of the company's pipeline and revenue prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-21T20:31:58.890613+00:00","company_name":"NewAmsterdam Pharma Co N.V.","ticker":"NAMSW","filing_date":"2026-09-21"}]}